(Source: Business Wire)
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced the appointment of Lawrence Gyenes to the position of Senior Vice President, Chief Financial Officer and Treasurer. Mr. Gyenes will direct and oversee the financial management, accounting, information services and investor relations activities of the Company, effective immediately.
Robert S. Mills, Columbia's president and chief executive officer, stated, "We are pleased to have Larry fill this important role, as he brings with him a strong financial and industry transaction background, as well as a demonstrated ability to communicate effectively with the investment community. We believe the depth and breadth of his experiences have prepared him well for his responsibilities at Columbia, and we look forward to his contributions as we execute our strategic plan to be a leading player in the infertility and women's reproductive healthcare markets."
Mr. Gyenes has over 35 years of financial experience in both privately and publicly held companies, most of which were in the life sciences industry. He most recently served as Senior Vice President and Chief Financial Officer of Acusphere, Inc., a former NASDAQ-listed specialty pharmaceutical company. Prior to joining Acusphere, Mr. Gyenes was Chief Financial Officer of Zila, Inc., a NASDAQ-listed oral cancer screening company, a consultant to investment management firms, and Senior Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc., a NASDAQ-listed specialty pharmaceutical company. He also held senior financial positions with Reliant Pharmaceuticals, Inc., Rand McNally & Co., CompuServe Corporation, Helene Curtis, Inc., and G.D. Searle & Co. and was a consultant to DuPont Pharmaceuticals Company in its sale to Bristol-Myers Squibb. Mr. Gyenes holds an MBA degree from the University of Chicago and a BS degree in Accounting from the University of Illinois.
About Columbia Laboratories
Columbia Laboratories, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the women's healthcare and endocrinology markets that use its novel bioadhesive drug delivery technology. Columbia markets CRINONE® 8% (progesterone gel) in the United States for progesterone supplementation as part of an ART treatment for infertile women with progesterone deficiency. The Company also markets STRIANT® (testosterone buccal system) for the treatment of hypogonadism in men. The Company's partners market CRINONE® 8%, STRIANT®, and three other products to additional U.S. and foreign markets.
